BRPI0600636A - processo para formulações de inibidores da enzima conversora de angiotensina e produto - Google Patents
processo para formulações de inibidores da enzima conversora de angiotensina e produtoInfo
- Publication number
- BRPI0600636A BRPI0600636A BRPI0600636-1A BRPI0600636A BRPI0600636A BR PI0600636 A BRPI0600636 A BR PI0600636A BR PI0600636 A BRPI0600636 A BR PI0600636A BR PI0600636 A BRPI0600636 A BR PI0600636A
- Authority
- BR
- Brazil
- Prior art keywords
- product
- converting enzyme
- angiotensin converting
- formulations
- enzyme inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0600636-1A BRPI0600636A (pt) | 2006-02-03 | 2006-02-03 | processo para formulações de inibidores da enzima conversora de angiotensina e produto |
| PCT/BR2007/000025 WO2007087700A1 (en) | 2006-02-03 | 2007-02-05 | Process for the preparation of formulations of angiotensin converting enzyme inhibitors and product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0600636-1A BRPI0600636A (pt) | 2006-02-03 | 2006-02-03 | processo para formulações de inibidores da enzima conversora de angiotensina e produto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0600636A true BRPI0600636A (pt) | 2007-10-30 |
Family
ID=37944773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0600636-1A BRPI0600636A (pt) | 2006-02-03 | 2006-02-03 | processo para formulações de inibidores da enzima conversora de angiotensina e produto |
Country Status (2)
| Country | Link |
|---|---|
| BR (1) | BRPI0600636A (pt-PT) |
| WO (1) | WO2007087700A1 (pt-PT) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111529695A (zh) * | 2020-04-30 | 2020-08-14 | 首都医科大学附属北京康复医院（北京工人疗养院） | 一种环糊精可溶性ace2及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0819004B2 (ja) * | 1986-12-26 | 1996-02-28 | 日清製粉株式会社 | 徐放性医薬製剤 |
| YU45837B (sh) * | 1988-01-18 | 1992-07-20 | LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. | Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom |
| SI9300470A (en) * | 1993-09-10 | 1995-04-30 | Lek Tovarna Farmacevtskih | Inclusion complexes of optically active and racemic ibuproxan with cyclodextrin derivates,process for their preparation,pharmaceutical preparations comprising the same and their use |
| JPH10194996A (ja) * | 1996-12-25 | 1998-07-28 | Janssen Pharmaceut Nv | アシル化シクロデキストリン含有製薬組成物 |
-
2006
- 2006-02-03 BR BRPI0600636-1A patent/BRPI0600636A/pt not_active Application Discontinuation
-
2007
- 2007-02-05 WO PCT/BR2007/000025 patent/WO2007087700A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007087700A1 (en) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR9704A (es) | Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma. | |
| EA200800726A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
| ECSP088560A (es) | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido | |
| CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
| BRPI0414581C1 (pt) | composto, composição farmacêutica compreendendo o referido composto e uso do referido composto | |
| AR063587A1 (es) | Preparcion liquida que comprende pimobendan | |
| BRPI0608402B8 (pt) | compostos de flavonóide e composições compreendendo os mesmos | |
| WO2008002646A3 (en) | Aerosol lotion formulations | |
| NO20083640L (no) | Antistoff-formulering | |
| RS51271B (sr) | Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid | |
| ES2130638T3 (es) | Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas. | |
| ATE485261T1 (de) | Salicylsäurederivate | |
| CY1112109T1 (el) | Σκευασμα αργατροβανης περιεχον ενα οξυ ως διαλυτοποιητη | |
| DK1311256T3 (da) | Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser | |
| RS53887B1 (en) | TOPICAL APPLICATION FOR ACTINIC KERATOSIS | |
| MA31567B1 (fr) | Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique | |
| BR112015026441A2 (pt) | derivados de fulereno aperfeiçoados e materiais, métodos e dispositivos relacionados | |
| DE60234329D1 (de) | Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2 | |
| MA29481B1 (fr) | Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase | |
| FR2804286B1 (fr) | Utilisation de derives de polyaminoacides comme agents conservateurs, compositions les comprenant et procede de conservation les utilisant | |
| YU59201A (sh) | Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina | |
| BR9913782A (pt) | Processo de preparação de uma formualação galênica que compreende fenofibrato como princìpio ativo, formulação galênica, medicamento e utilizações de um meio lìquido e de partìculas de fenofibrato | |
| RS54140B1 (en) | USE OF 24-ORDER | |
| MA29922B1 (fr) | NOUVEAUX DERIVES DE BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE CMet | |
| CY1116189T1 (el) | Σταθερη υγρη φαρμακευτικη συνθεση με βαση την τραζοδονη |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
| B09B | Decision: refusal | ||
| B09B | Decision: refusal |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |